Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

ProBioGen licenses GlymaxX technology to Thermo Fisher
July 2016
SHARING OPTIONS:

BERLIN & FREIBURG, Germany—Thermo Fisher Scientific has licensed ProBioGen’s GlymaxX technology for use in developing allergy diagnostics, the latter reported recently. This technology prevents the synthesis of the sugar fucose in cells stably modified with a specific enzyme-encoding gene. GlymaxX cell lines can either produce afucosylated antibodies or stably produce fucosylated antibodies again with an adjusted degree of fucosylation. Afucosylation offers a more accurate assessment of allergic sensitization.
 
“Deviating from the typical GlymaxX application of enhancing the cell-killing potency of CHO-derived therapeutic antibodies in cancer, GlymaxX plays out its universal applicability in a radically different field,” said ProBioGen’s chief scientific officer, Dr. Volker Sandig. “In this case, GlymaxX acts to prevent the formation of cross-reactive carbohydrate determinants on recombinant proteins, expressed in insect cells, which would otherwise cause the detection of IgE antibodies of a certain kind with no clinical significance. Thus, this sophisticated technology serves to add to the specificity of the diagnostics test result.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.